ATNM icon

Actinium Pharmaceuticals

1.46 USD
-0.06
3.95%
At close May 14, 4:00 PM EDT
After hours
1.50
+0.04
2.74%
1 day
-3.95%
5 days
5.04%
1 month
10.61%
3 months
26.96%
6 months
-11.52%
Year to date
15.87%
1 year
-85.24%
5 years
-72.91%
10 years
-98.06%
 

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Employees: 37

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,417% more call options, than puts

Call options by funds: $91K | Put options by funds: $6K

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

1.09% less ownership

Funds ownership: 27.16% [Q3] → 26.07% (-1.09%) [Q4]

4% less funds holding

Funds holding: 72 [Q3] → 69 (-3) [Q4]

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

36% less capital invested

Capital invested by funds: $15.9M [Q3] → $10.2M (-$5.65M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$4
174%
upside
Avg. target
$4
174%
upside
High target
$4
174%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
21% 1-year accuracy
81 / 389 met price target
174%upside
$4
Buy
Reiterated
12 May 2025

Financial journalist opinion

Based on 255 articles about ATNM published over the past 30 days

Neutral
Accesswire
4 hours ago
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM) - Join by May 27, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148580&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM) - Join by May 27, 2025 - Contact Levi & Korsinsky
Neutral
Accesswire
10 hours ago
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) Investors - Lead Plaintiff Deadline on May 27, 2025
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148544&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) Investors - Lead Plaintiff Deadline on May 27, 2025
Neutral
GlobeNewsWire
10 hours ago
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders.
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
Neutral
Accesswire
11 hours ago
May 27, 2025 Deadline: Join Class Action Lawsuit Against Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148536&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
May 27, 2025 Deadline: Join Class Action Lawsuit Against Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky
Neutral
Accesswire
11 hours ago
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 26 Deadline in Securities Class Action - ATNM
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025.
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 26 Deadline in Securities Class Action - ATNM
Neutral
Accesswire
12 hours ago
Actinium Pharmaceuticals, Inc. (ATNM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 27, 2025 Deadline
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148520&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
Actinium Pharmaceuticals, Inc. (ATNM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 27, 2025 Deadline
Neutral
GlobeNewsWire
12 hours ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
Neutral
Accesswire
16 hours ago
Contact Levi & Korsinsky by May 27, 2025 to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148482&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Contact Levi & Korsinsky by May 27, 2025 to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)
Neutral
Accesswire
17 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Neutral
Accesswire
19 hours ago
Securities Lawsuit Alert: Actinium Pharmaceuticals, Inc. (ATNM) Investors - Contact Levi & Korsinsky Before May 27, 2025
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148395&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq.
Securities Lawsuit Alert: Actinium Pharmaceuticals, Inc. (ATNM) Investors - Contact Levi & Korsinsky Before May 27, 2025
Charts implemented using Lightweight Charts™